Intensity Therapeutics pauses INVINCIBLE-4 enrollment after skin irritation; first Cohort A patient achieves pCR

INTENSITY THERAPEUTICS, INC.

First patient in Cohort A achieved pathological complete response after two INT230-6 doses plus immunochemotherapy.
Cohort A patients received INT230-6 eight days apart followed by standard-of-care immunochemotherapy.
Safety profile described as favorable, but localized skin irritation near tumor site observed in some patients.
Enrollment paused to evaluate data and implement adjustments before reopening.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.